Overview

* Tyra Biosciences ( TYRA ) Q2 net loss widens to $28.1 mln from $18.7 mln last year

* Basic EPS beats analyst expectations, despite increased R&D and G&A expenses

* Co dosed first patient in SURF302 Phase 2 bladder cancer study

Outlook

* Tyra expects cash reserves to support operations through at least 2027

* Company anticipates Phase 2 readouts in SURF302 and BEACH301

* Tyra sees significant opportunity in FGFR3-targeted therapies for bladder cancer

* Company plans to dose first child in BEACH301 study in 3Q 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$28.10

Income mln

Q2 Basic Beat -$0.47 -$0.53

EPS (8

Analysts

)

Q2 Beat -$31.45 -$33.50

Operatin mln mln (8

g Income Analysts

)

Q2 $31.45

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Tyra Biosciences Inc ( TYRA ) is $30.00, about 64.2% above its August 13 closing price of $10.75

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)